Coherus Oncology, Inc.(CHRS)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,955 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
Unusual Activity in CHRS
Events flagged as statistical outliers against CHRS's own multi-year baseline — not fixed dollar thresholds.
- Score shock2026-08-05
CHRS quality score dropped 15 points (43→28) on a new filing
View source filing →
CHRS Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Coherus Oncology, Inc. (CHRS), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CHRS at 5.0/100 on a 32-signal composite quality model, placing it at rank #2,955 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue growth (0.8) and free cash flow (3.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 5.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Coherus Oncology, Inc. reports quarterly revenue of $14.3M, net income of $-20.6M. Top institutional holders of CHRS by reported 13-F value include Timothy G. Youngquist 2020 Irrevocable, BlackRock, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. CHRS trades on the Nasdaq exchange and files with the SEC under CIK 1512762. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CHRS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Coherus Oncology, Inc. directly from SEC EDGAR. Coherus Oncology, Inc.'s 13F Pro composite quality score has ranged between 5 and 41 since 2025, currently 5.0 — a declining long-term trajectory across 52 quarterly and live scoring snapshots.
Revenue
Q2 2026
$14.3M
Net Income
Q2 2026
$-20.6M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+59.8% YoYNet Income
+489.4% YoYOperating Income
+9.3% YoYEPS (Diluted)
+472.0% YoYTotal Assets
-42.4% YoYOp. Cash Flow
-577.7% YoYFree Cash Flow
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $42.2M +59.8% | $26.4M -89.7% | $257.2M +21.9% | $211.0M -35.4% | $326.6M -31.4% | $475.8M |
| Net Income | $168.0M +489.4% | $28.5M +112.0% | $-237.9M +18.5% | $-291.8M -1.6% | $-287.1M -317.1% | $132.2M |
| Operating Income | $-181.1M +9.3% | $-199.7M +1.7% | $-203.2M +20.9% | $-256.9M +2.6% | $-263.9M -268.8% | $156.3M |
| EPS (Diluted) | $1.43 +472.0% | $0.25 +109.9% | $-2.53 +32.7% | $-3.76 +1.3% | $-3.81 -335.2% | $1.62 |
| Total Assets | $258.3M -42.4% | $448.5M -28.8% | $629.6M +30.9% | $480.8M -29.2% | $679.3M -19.3% | $841.6M |
| Operating Cash Flow | $-138.5M -577.7% | $-20.4M +88.3% | $-174.9M +27.5% | $-241.1M -544.2% | $-37.4M -124.3% | $154.1M |
| Free Cash Flow | — | — | $-175.2M +28.0% | $-243.2M -528.0% | $-38.7M -126.4% | $146.9M |
Get alerted when CHRS's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Coherus Oncology, Inc. including:
Top Institutional Holders of CHRS
Timothy G. Youngquist 2020 Irrevocable Trust
$18.3M13,050,623 shBlackRock, Inc.
$16.8M12,003,316 shVANGUARD CAPITAL MANAGEMENT LLC
$8.3M5,949,490 shGEODE CAPITAL MANAGEMENT, LLC
$5.2M3,685,567 shSamsara BioCapital, LLC
$4.8M3,428,571 shKohlberg Kravis Roberts & Co. L.P.
$4.2M3,036,076 shSTATE STREET CORP
$3.3M2,382,305 shTWO SIGMA INVESTMENTS, LP
$3.2M2,259,412 shCM Management, LLC
$2.9M2,100,000 shC WorldWide Group Holding A/S
$2.7M1,928,464 sh
| Fund | Value | Shares |
|---|---|---|
| Timothy G. Youngquist 2020 Irrevocable Trust | $18.3M | 13,050,623 |
| BlackRock, Inc. | $16.8M | 12,003,316 |
| VANGUARD CAPITAL MANAGEMENT LLC | $8.3M | 5,949,490 |
| GEODE CAPITAL MANAGEMENT, LLC | $5.2M | 3,685,567 |
| Samsara BioCapital, LLC | $4.8M | 3,428,571 |
| Kohlberg Kravis Roberts & Co. L.P. | $4.2M | 3,036,076 |
| STATE STREET CORP | $3.3M | 2,382,305 |
| TWO SIGMA INVESTMENTS, LP | $3.2M | 2,259,412 |
| CM Management, LLC | $2.9M | 2,100,000 |
| C WorldWide Group Holding A/S | $2.7M | 1,928,464 |
Companies Similar to CHRS
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
X4 Pharmaceuticals, Inc
AGIOS PHARMACEUTICALS, INC.
BICYCLE THERAPEUTICS PLC
AbCellera Biologics Inc.
Ovid Therapeutics Inc.
Crinetics Pharmaceuticals, Inc.
OmniAb, Inc.
Foghorn Therapeutics Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put CHRS on your watchlist
Track score changes the day Coherus Oncology, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is CHRS a good stock to buy?
13F Pro's AI-powered analysis of Coherus Oncology, Inc. (CHRS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CHRS are available on the CHRS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. CHRS is classified as a small company.
Which hedge funds own CHRS?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CHRS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Coherus Oncology, Inc.'s investment landscape.